Biolinq, a San Diego, CA-based healthcare technology company, raised $58M in funding.
The round was led by Alpha Wave Ventures, with participation from Niterra’s corporate venture capital fund jointly operated with Pegasus Tech Ventures and existing investors RiverVest Venture Partners, AXA IM Alts, Global Health Investment Corporation, Aphelion Capital, Senvest Management, Features Capital and Taisho Pharmaceutical.
The company intends to use the funds to support completion of a U.S. pivotal clinical trial this year, evaluating its proprietary intradermal glucose sensor, and subsequent FDA submission.
Led by CEO Rich Yang, Biolinq is a healthcare technology company providing precision multi-analyte wearable sensors to improve metabolic health. The technology is designed to provide a better view of metabolic health by combining glucose information with context around activities of daily living in one device.
Commenting on the news, Rich Yang said: “Our technology approach enables access to a coveted, metabolically active compartment of the skin for biosensing without the use of introducer needles or bleeding.”
FinSMEs
04/04/2024